Researchers face difficulty in conducting experiments to determine the impact of drug timing on survival due to the need for diverse patients and assigning them random time slots. Results from a study published in Lancet Oncology suggest that patients with metastatic melanoma who receive immunotherapy infusions after 4.30 pm do not live as long as those who receive them earlier.